Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Invested Capital (2017 - 2026)

Denali Therapeutics has reported Invested Capital over the past 9 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly Invested Capital fell 17.73% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 17.73% year-over-year, with the annual reading at $1.0 billion for FY2025, 17.73% down from the prior year.
  • Invested Capital was $1.0 billion for Q4 2025 at Denali Therapeutics, up from $931.8 million in the prior quarter.
  • Over five years, Invested Capital peaked at $1.5 billion in Q1 2024 and troughed at $812.7 million in Q3 2022.
  • The 5-year median for Invested Capital is $1.0 billion (2022), against an average of $1.1 billion.
  • Year-over-year, Invested Capital skyrocketed 113.62% in 2021 and then decreased 29.63% in 2025.
  • A 5-year view of Invested Capital shows it stood at $962.3 million in 2021, then grew by 8.78% to $1.0 billion in 2022, then decreased by 1.52% to $1.0 billion in 2023, then rose by 20.18% to $1.2 billion in 2024, then decreased by 17.73% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Invested Capital are $1.0 billion (Q4 2025), $931.8 million (Q3 2025), and $1.0 billion (Q2 2025).